Apr 12, 2021 / 12:30PM GMT
Operator
Hello, and welcome to the Incyte data highlights on the adenosine program from AACR 2021. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Christine Chiou. Please go ahead.
Christine Chiou - Incyte Corporation - Head of IR
Thank you, Kevin. Good morning, and welcome to Incyte's adenosine program highlights from AACR conference call and webcast. The slides used today are available for download on the Investors section of incyte.com. I'm joined on the call today by Steven Stein, our Chief Medical Officer; and by Patrick Mayes, Incyte's Vice President of Biotherapeutics Research. Also joining for the Q&A session following our prepared remarks, Dash Dhanak, our Chief Scientific Officer.
Before we begin, I would like to remind you that safe harbor rules govern our remarks today and any forward-looking statements that we may make. I, therefore, encourage you to review the risk factors detailed in Incyte's SEC filings included in our Form 10-K for the year ended December 31, 2020.
Incyte Corp Data Highlights on Adenosine Program from AACR 2021 Transcript
Apr 12, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers